Sign up
Pharma Capital

Q BioMed 'looking for a significant return for shareholders' - CEO Denis Corin

Denis Corin, chief executive of Q BioMed (OTCMKTS:QBIO) tells Proactive's Andrew Scott their objective is to find innovative, under-valued and under-appreciated biotech assets out in the pharma world and bring them in-house through licensing and option agreements.

''[We're] agnostic in terms of exit .... as long as there's a significant return for shareholders'', Corin says.


View full QBIO profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.